Publications by authors named "Bandi Ramanjineyulu"
Background: This phase 1, randomized, one-day, five-period crossover study in adults with type 1 diabetes on continuous subcutaneous insulin infusion investigated local infusion site pain following infusion of the excipients of ultra rapid lispro (URLi; without insulin) across infusion sites and depths.
Methods: Forty participants (mean age, 40.5 years; body mass index [BMI], 27.
Article Synopsis
- - Daprodustat is a drug being tested for treating anemia in patients with chronic kidney disease, and this study examined how liver impairment affects its metabolism and safety.
- - Participants with mild and moderate liver issues showed increased levels of daprodustat and its metabolites compared to healthy controls, with a 1.5- to 2.0-fold increase in drug exposure.
- - Despite the higher drug levels in those with liver impairment, there were no significant changes in erythropoietin (EPO) levels, and no serious side effects were reported during the study.
Article Synopsis
- Daprodustat, an oral medication being tested for treating anemia in chronic kidney disease, has undergone a study assessing its absorption, distribution, and excretion after both oral and IV doses in healthy men.
- The study found that about 95% of the radiolabeled substance was recovered by day 5, primarily through feces, indicating it is mostly eliminated via the liver and intestines rather than the kidneys.
- Daprodustat showed moderate oral bioavailability (about 66%) and low tissue distribution, with no serious side effects reported, suggesting it is generally well tolerated.
Article Synopsis
- Current treatments for anemia in chronic kidney disease (CKD) include iron supplements, blood transfusions, and erythropoietin replacement but have limitations; daprodustat is a new oral medication in Phase 3 trials that may overcome some of these issues.
- The study aimed to evaluate the pharmacokinetics (how the drug behaves in the body) of daprodustat in different groups: those with normal kidney function, CKD patients not on dialysis, and those on hemodialysis (HD) or peritoneal dialysis (PD).
- Results showed similar pharmacokinetic properties for daprodustat across all patient groups, indicating consistent absorption and metabolism, even in those undergoing dialysis. *